Form 4: Sutro Biopharma Executive Jane Chung Reports Stock Transactions

Jane Chung, President and COO of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Summary

• On March 1, 2024, Jane Chung, President and COO of Sutro Biopharma, had restricted stock units (RSUs) vest, resulting in the acquisition of 6,875 shares of common stock.
• Simultaneously, 2,038 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement, at a price of $4.95 per share.
• Following these transactions, Chung directly owns 36,535 shares of Sutro Biopharma common stock and 20,625 restricted stock units.
• The vesting of the RSU award occurs annually, with 1/4th of the total award vesting each year beginning on March 1, 2024, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions, and does not contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.

Key Dates